<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> and <z:hpo ids='HP_0000822'>hypertension</z:hpo> are closely associated and contribute together to microvascular and macrovascular end-organ damage </plain></SENT>
<SENT sid="1" pm="."><plain>Prevalence of <z:hpo ids='HP_0000822'>hypertension</z:hpo> is increased even in the <z:e sem="disease" ids="C0362046" disease_type="Disease or Syndrome" abbrv="">prediabetic state</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>However, there is little information available about the relationship between incidence of <z:hpo ids='HP_0000822'>hypertension</z:hpo> and a deterioration of <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance from <z:hpo ids='HP_0000833'>impaired glucose tolerance</z:hpo> (IGT) to <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: To clarify these issues we analysed data from the Stop non <z:hpo ids='HP_0100651'>insulin dependent diabetes mellitus</z:hpo> (STOP-<z:mp ids='MP_0002057'>NIDDM</z:mp>) trial - a prospective interventional study for the prevention of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> in people with <z:e sem="disease" ids="C0362046" disease_type="Disease or Syndrome" abbrv="">prediabetes</z:e> using the alpha-glucosidase inhibitor <z:chebi fb="0" ids="2376">acarbose</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0000822'>Hypertension</z:hpo> was already present at study entry in 702 (51.3%) of 1368 patients who were eligible for intention-to-treat analysis </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: A total of 96 out of the 666 normotensive individuals at baseline developed <z:hpo ids='HP_0000822'>hypertension</z:hpo> during the 3.3-year follow-up </plain></SENT>
<SENT sid="6" pm="."><plain>The strongest risk factors for time to development of <z:hpo ids='HP_0000822'>hypertension</z:hpo> were abdominal <z:hpo ids='HP_0001513'>obesity</z:hpo> at baseline [hazard ratio 1.91, 95% confidence interval (CI) 1.19-3.05, P &lt; 0.01] and worsening of <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance (hazard ratio 1.54, 95% CI 1.02-2.32, P &lt; 0.05), whereas <z:chebi fb="0" ids="2376">acarbose</z:chebi> treatment reduced the risk of <z:hpo ids='HP_0000822'>hypertension</z:hpo> (hazard ratio 0.59, 95% CI 0.39-0.90, P &lt; 0.05) </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSION: A significant relationship was found between the development of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and <z:hpo ids='HP_0000822'>hypertension</z:hpo> in patients with IGT, and treatment with <z:chebi fb="0" ids="2376">acarbose</z:chebi>, which primarily improved postprandial <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e>, reduced the incidence of <z:hpo ids='HP_0000822'>hypertension</z:hpo> as well as <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="8" pm="."><plain>This suggests that the two entities shared 'common soil' </plain></SENT>
</text></document>